Clinical Trial Update: Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab in HTLV-1–associated adult T-cell leukemia/lymphoma has completed and results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Htlv-1 Infection
• Lymphomatous Adult T-cell Leukemia Lymphoma
• Smoldering Adult T-cell Leukemia Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-03-01